aureus. Fortunately ... and tigecycline are representants of three novel antibacterial classes for the treatment of infections caused by MRSA. In the following section novel antibacterials ...

GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 /RELIEF THERAPEUTICS (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the ...

Demand for secondhand and vintage clothing has surged within the last few years. Pre-owned fashion is seen by many consumers ...

However, a little-known treatment dating back to the First World War is available, if NHS doctors are prepared to spend ...

Staphylococcus aureus, mostly known from its antibiotic ... showcasing its potential as a non-toxic antimicrobial treatment. The research paper highlights critical contamination points in the ...

The manuscript explores how bacterial evolution in the presence of lytic phages modulates b-lactams resistance and virulence properties in methicillin-resistant Staphylococcus aureus (MRSA). The work ...

The CLEAR-IE registry data, which show clinical efficacy, are just the first step—an RCT may be forthcoming, researchers say.

Antibiotics have saved millions of lives from infectious diseases and are considered one of the most important discoveries of ...

Dr Leah Smith, a research fellow at the University of Otago, has been awarded the 2024 L’Oréal-UNESCO For Women in Science Fellowship for her research into phage therapy – an evolving field that looks ...

GENEVA, SWITZERLAND / ACCESSWIRE / October 8, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering ...

Ventilator-associated pneumonia (VAP) is the most common ICU infection, affecting up to 20% of critically ill patients with a ...